ClinicalTrials.gg

Program

CDK2 Inhibitor AVZO-021

Its studies are mostly in Carcinoma, Ovarian Epithelial · Breast Neoplasms, led by Avenzo Therapeutics.

Furthest: phase 2, since Apr 13, 20232 company-led studies, 2 open or runningNext primary completion: Jan 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Avenzo Therapeutics22 open or runningphase 2since Apr 13, 2023Apr 13, 2023Jan 31, 2028phase 2 · NCT05867251

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 13, 2023First study: phase 2 study in Carcinoma, Ovarian EpithelialFirst studyNCT05867251 · 430 planned · United States, Australia
  2. May 22, 2025Phase 2 study in HR+/HER2- Breast CancerNCT06998407 · 380 planned · United States

Ahead

  1. Jan 31, 2028Primary completion: phase 2 study in Carcinoma, Ovarian EpithelialNCT05867251
  2. Aug 2028Primary completion: phase 2 study in HR+/HER2- Breast CancerNCT06998407

TargetBeta

CDK2 →read by rule
“An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), ”NCIt, by rule

Other programs on CDK2

ProgramCompanyFurthest phaseStudies
culmerciclibSino Biopharmaceuticalphase 311
CDK2 Inhibitor INCB123667ruleIncytephase 37
tegtociclibPfizerphase 24
vustanaciclibregor-pharmaceuticals-incphase 23
CDK2 Inhibitor ECI830Novartisphase 21
CDK2 Degrader BG-75098ruleBeOne Medicinesphase 11
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11
nkt5097 cdk2rulenikang-therapeutics-incphase 11
ZE94-0605ruleeilean-therapeuticsphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06998407HR+/HER2- Breast Cancer · United States2RecruitingAug 2028380
NCT05867251Carcinoma, Ovarian Epithelial · United States, Australia2RecruitingJan 31, 2028430

How it is read

Names in the registry

  • “AVZO-021”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.